DOP Session 4

DOP28-36

  • 17:30-18:30 Digital Oral Presentation Session 4: Practicalities of IBD patient care
    Room: C1-M3, Hall C, Bella Center
    Chairs: Uri Kopylov, Tel Aviv, Israel
    Fernando Magro, Porto, Portugal
      17:30-17:36 DOP28: Maternal obstetric outcomes in women with IBD compared to the general population
    G. Lever1, T. Glanville1, C. Selinger2
    1
    Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2Leeds Teaching Hospitals NHS Trust, Gastroenterology, Leeds, United Kingdom 
      17:36-17:42 DOP29: Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF or conventional therapy
    A. Moens1,2 , C. van der Woude3, M. Julsgaard4, S. Sebastian5, 6, N. Arebi7, M. Alzinaty7, E. Humblet8, K. B. Kok9, J. Sheridan10, C. Gilletta De Saint-Joseph11, S. Nancey12, J.-F. Rahier13, P. Bossuyt14, A. Cremer15, S. Dewit16, C. Eriksson17, F. Hoentjen18, T. Krause19, E. Louis20, E. Macken21, Z. Milenkovic22, J. Nijs23, A. Posen24, A. Van Hootegem25, W. Van Moerkercke26, S. Vermeire1, 2, A. Bar-Gil Shitrit27, M. Ferrante1, 2
    1
    University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2Catholic University Leuven, Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 3Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, 4Aarhus University Hospital, Department of Gastroenterology and Hepatology, Aarhus, Denmark, 5Hull & East Yorkshire NHS Trust, IBD Unit, Hull, United Kingdom, 6University of Hull & York, Hull York Medical School, Hull, United Kingdom, 7St. Marks Hospital, Department of Gastroenterology, London, United Kingdom, 8Ziekenhuis Oost-Limburg - Campus Sint-Jan, Department of Gastroenterology, Genk, Belgium, 9Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom, 10St. Vincent’s University Hospital, Department of Gastroenterology, Dublin, Ireland, 11Hôpital Rangueil, Department of Gastroenterology, Toulouse, France, 12CHU Lyon, Department of Gastroenterology and Hepatology, Lyon, France, 13CHU UCL Namur, Université catholique de Louvain, Deparment of Gastroenterology, Yvoir, Belgium, 14Imeldaziekenhuis, Department of Gastroenterology, Bonheiden, Belgium, 15Hôpital Erasme, Université Libre de Bruxelles, Department of Gastroenterology, Brussels, Belgium, 16Mariaziekenhuis Noord-Limburg, Department of Gastroenterology, Overpelt, Belgium, 17Faculty of Medicine and Health Orebro University, Department of Gastroenterology, Orebro, Sweden, 18Radboud UMC, Department of Gastroenterology, Nijmegen, Netherlands, 19Opernstrasse, Department of Gastroenterology, Kassel, Germany, 20CHU Liège, Department of Gastroenterology, Liège, Belgium, 21Universiteit ziekenhuis Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, 22Military Medical Academy Belgrade, Department of Gastroenterology, Belgrade, Serbia, 23Sint-Trudo Ziekenhuis, Department of Gastroenterology, St-Truiden, Belgium, 24AZ Vesalius, Department of Gastroenterology, Tongeren, Belgium, 25AZ Klina, Department of Gastroenterology, Brasschaat, Belgium, 26AZ Groeninge, Department of Gastroenterology, Kortrijk, Belgium, 27Shaare Zedek Medical Center, Hebrew University Jerusalem, Digestive diseases institute, Jerusalem, Israel
      17:42-17:48 DOP30: Factors associated with life satisfaction in people with Crohn's Disease and Ulcerative Colitis: Results from the national 2018 Crohn's and Colitis UK Inflammatory Bowel Disease Quality of Life Survey
    G. Rowse1, S. Hollobone2, S. Afhim2, P. Oliver3
    1
    University of Sheffield, Clinical Psychology Unit, Sheffield, United Kingdom, 2Crohn's and Colitis UK, St Albans, United Kingdom, 3University of Sheffield, Academic Unit of Primary Medical Care, Sheffield, United Kingdom
      17:48-17:54 DOP31: Development and validation of the IBD-REFER criteria: When should a general practitioner or paediatrician refer a patient for suspected IBD?
    O. Atia1, G. Focht1, A. Assa2, B. Yerushalmi3, R. Shaoul4, D. S. Shouval5, A. Bar-Gil Shitrit6, B. Koslowsky6, I. Dotan7, R. Kariv8, E. Lavon8, D. Turner1
    1
    Institute of Pediatric Gastroenterology, The Hebrew University of Jerusalem, Jerusalem, Israel, 2Schneider Children's Hospital, Petach Tikva, Israel, 3Soroka University Medical Center and Faculty of Pediatric Gastroenetrology Unit, Health Sciences, Beer-Sheva, Israel, 4Pediatric Gastroenterology Institute, Ruth Children's Hospital, Rambam Medical Center, Haifa, Israel, 5Pediatric Gastroenterology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat gan, Israel, 6Digestive diseases institute , Shaare Zedek Medical Center, Jerusalem, Israel, 7Division of Gastroenterology, Rabin Medical Center, Sackler Faculty of Medicine, Petach Tikva, Israel, 8Health Division, Maccabi Healthcare Services, Jerusalem, Israel
      17:54-18:00 DOP32: Withdrawal of thiopurines in Crohn’s Disease treated with scheduled adalimumab maintenance: A prospective randomised clinical trial (DIAMOND2)
    T. Hisamatsu1, S. Kato2, R. Kunisaki3, M. Matsuura4, M. Nagahori5, S. Motoya6, M. Esaki7, N. Fukata8, S. Inoue9, T. Sugaya10, H. Sakuraba11, F. Hirai12, K. Watanabe13, 14, T. Kanai15, M. Naganuma15, H. Nakase16, Y. Suzuki17, M. Watanabe5, T. Hibi18, M. Nojima19, T. Matsumoto201, DIAMOND2 Study Group
    1Kyorin University School of Medicine, The Third Department of Internal Medicine, Tokyo, Japan, 2Saitama Medical Centre, Saitama Medical University, Department of Gastroenterology and Hepatology, Saitama, Japan, 3Yokohama City University Medical Center, Inflammatory Bowel Disease Centre, Kanagawa, Japan, 4Graduate School of Medicine, Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan, 5Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, 6Sapporo Kosei General Hospital, Inflammatory Bowel Disease Center, Sapporo, Japan, 7Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan, 8Kansai Medical University, Third Department of Internal Medicine, Osaka, Japan, 9Kobe City Medical Center General Hospital, Departments of Gastroenterology, Hyogo, Japan, 10Japan Red Cross Ashikaga Hospital, Department of Internal Medicine, Tochigi, Japan, Japan, 11Hirosaki University Graduate School of Medicine, Department of Gastroenterology and Hematology, Hirosaki, Japan, 12Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, 13Osaka City General Hospital, Division of Gastroenterology,, Osaka, Japan, 14Hyogo College of Medicine, Department of Intestinal Inflammation Research, Nishinomiya, Japan, 15Keio University, Department of Internal Medicine, School of Medicine, Tokyo, Japan, 16Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan, 17Toho University Sakura Medical Center, Department of Internal Medicine, Sakura, Japan, 18Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan, 19Institute of Medical Science Hospital, University of Tokyo, Center for Translational Research, Tokyo, Japan, 20Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan  
       18:00-18:06 DOP33: Long-term clinical efficacy of ustekinumab in refractory Crohn’s Disease: A multi-centre Belgian cohort study
    C. Liefferinckx1 B. Verstockt2, A. Gils3, M. Noman2, C. Van Kemseke4, E. Macken5, M. De Vos6, W. Van Moerkercke7, J.-F. Rahier8, P. Bossuyt9, J. Dutré10, E. Humblet11, D. Staessen12, H. Peters13, P. Van Hootegem14, E. Louis4, D. Franchimont1, F. Baert15, S. Vermeire2
    1
    Hopital Erasme - ULB, Department of Gastroenterology, Brussels, Belgium, 2University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 3KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 4Centre Hospitalier Universitaire Sart-Tilman - ULG, Department of Gastroenterology, Liège, Belgium, 5Universiteit ziekenhuis Antwerpen - UZA, Department of Gastroenterology, Antwerpen, Belgium, 6Universitair ziekenhuis Gent, Department of Gastroenterology, Gent, Belgium, 7AZ Groeninge, Department of Gastroenterology, Kortrijk, Belgium, 8Centre Hospitalier Universitaire Mont-Godinne - UCL, Department of Gastroenterology, Yvoir, Belgium, 9Imeldaziekenhuis, Department of Gastroenterology, Bonheiden, Belgium, 10Ziekenhuis Netwerk Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, 11Ziekenhuis Oost-Limburg - Campus Sint-Jan, Department of Gastroenterology, Genk, Belgium, 12GZA Sint-Vincentius ziekenhuis, Department of Gastroenterology, Antwerpen, Belgium, 13Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Gent, Belgium, 14Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Brugge, Belgium, 15AZ Delta, Department of Gastroenterology, Roeselare-Menen, Belgium
       18:06-18:12 DOP34: Disease activity patterns during the first 5 years after diagnosis in children with Ulcerative Colitis: A population-based study
    M. Aloi1, M. Bramuzzo2, L. Norsa3, S. Arrigo4, M. Distante5, E. Miele6, A. Agrusti2, C. Romano7, C. Giobbi5, R. Panceri8, L. D'Antiga3, S. Cucchiara5, P. Alvisi9, SIGENP IBD Working Group
    1Sapienza University of Rome, Department of Pediatrics, Pediatric Gastroenterology Unit, Rome, Italy, 2Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, 3Ospedale Papa Giovanni XXIII, Pediatric Gastroenterology Hepatology and Nutrition, Bergamo, Italy, 4Istituto Giannina Gaslini, Department of Gastroenterology and Endoscopy, Genoa, Italy, 5Sapienza University of Rome, Department of Pediatric Gastroenterology, Rome, Italy, 6University of Naples "Federico II", Department of Translational Medical Science, Section of Pediatrics, Naples, Italy, 7University of Messina, Department of Pediatric Gastroenterology and Endoscopy, Messina, Italy, 8San Gerardo Hospital, Monza, Italy, 9Maggiore Hospital, Bologna, Italy  
      18:12-18:18 DOP35: Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn's Disease, is significantly amplified in patients with a complicated phenotype
    R. S. Choung1F. Petralia2, J. Torres3, 4, T. Sato5, X.-j. Li6, P. Wang2, S. Telesco5, C. Porter7, R. Laird7, R. Gutierrez7, F. Princen6, S. Plevy5, R. Strauss5, M. Riddle7, J. Murray1, J. F. Colombel3, PREDICTS (PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-­service Subjects) study group
    1Mayo Clinic, Gastroenterology and Hepatology, Rochester, United States, 2Icahn School of Medicine, Genetics and Genomic Sciences, New York, United States, 3Icahn School of Medicine at Mount Sinai, New York, United States, 4Hospital Beatriz Ângelo, Lisbon, Portugal, 5Janssen R&D, Spring House, United States, 6Prometheus Laboratories Inc., San Diego, United States, 7Naval Medical Research Center, Silver Spring, United States
      18:18-18:24  DOP36: Gut microbial variations in patients with quiescent Crohns Disease predict subsequent disease flare
    T. Braun1, A. Di Segni1, M. BenShoshan1, S. Neuman1, O. Picard1, K. Sosnovski1, G. Efroni1, B. Weiss1, D. Yablecovitch1, A. Lahat1, R. Eliakim1, U. Kopylov1, S. Ben-Horin1, Y. Haberman1, 2, On behalf of Israeli IBD Research Nucleus (IIRN)
    1Sheba Medical Center, Tel Hashomer, Israel, 2Cincinnati Children Hospital Medical Center, Cincinnati, United States

Digital Oral Presentations
(as of January 2019)

  • DOP Session 1 Advances in IBD pathophysiology
    DOP01-09
    Room: C1 M1
    Chairs: Javier Gisbert, Madrid, Spain
    Maximilian Waldner, Erlangen, Germany
    DOP Session 2 Mechanisms of intestinal inflammation
    DOP10-18
    Room: C1 M0
    Chairs: Loris Riccardo Lopetuso, Rome, Italy
    Britta Siegmund, Berlin, Germany
    DOP Session 3 Translational science in IBD
    DOP19-27
    Room: C1 M2
    Chairs: Peter Bossuyt, Bonheiden, Belgium
    Axel Dignass, Frankfurt, Germany
    DOP Session 4 Practicalities of IBD patient care
    DOP28-36
    Room: C1 M3
    Chairs: Uri Kopylov, Tel Aviv, Israel
    Fernando Magro, Porto, Portugal
    DOP Session 5 Old and new treatment
    DOP37-45
    Room: C1 M4-5
    Chairs: Paolo Gionchetti, Bologna, Italy
    Anne Strik, Amsterdam, The Netherlands
  • DOP Session 6 Novel treatments
    DOP46-54
    Room C1 M4-5
    Chairs: Marc Ferrante, Leuven, Belgium
    Gionata Fiorino, Rome, Italy
    DOP Session 7 Recent advances of biologic therapies
    DOP55-63
    Room: C1 M3
    Chairs: Filip Baert, Roeselare, Belgium
    Shomron Ben-Horin, Ramat Gan, Israel
    DOP Session 8 Intestinal healing
    DOP64-72
    Room: C1 M2
    Chairs: Raja Atreya, Erlangen, Germany
    Marietta Iacucci, Birmingham, United Kingdom
    DOP Session 9 Surgery and IBD
    DOP73-81
    Room: C1 M1
    Chairs: Paulo Kotze, Curitiba, Brazil
    Andre D'Hoore, Leuven, Belgium
    DOP Session 10 Clinical epidemiology
    DOP82-90
    Room: C1 M0
    Chairs: Stefanos Bonovas, Milan, Italy
    Johan Burisch, Copenhagen, Denmark